• Skip to navigation
  • Skip to main content

Polyneuron Pharmaceuticals

  • Home
  • Technology
  • Pipeline
  • Company
  • Careers
  • Contact
  • News

Polyneuron
News & Developments

  • April 23, 2021 General
    Polyneuron and University of Basel awarded grant of CHF 1.2 M to advance novel treatments to support ABO-Incompatible transplants

    Polyneuron is proud to announce that – together with the University of Basel – we awarded grant of CHF 1.2M to advance novel treatments to support ABO-Incompatible transplants. Press Release… [read on]

  • October 7, 2020 Uncategorized
    Polyneuron appoints Aled Williams as chief business officer

    We are extremely pleased to welcome Aled Williams to Polyneuron as our new Chief Business Officer. Aled brings more than 25 years’ of leadership experience across both pharmaceutical and biotech sectors. Press Release… [read on]

  • September 16, 2020 General
    Polyneuron extends Series A to CHF 36.5 million

    Polyneuron announces a CHF 14 million extension of the Series A, bringing the total to CHF 36.5 million. HBM Healthcare Investments has joined the consortium of investors in the Series A, led by Sofinnova Partners, and which included New Enterprise Associates (NEA) and other private… [read on]

  • June 5, 2020 General
    Polyneuron's PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy

    Polyneuron is proud to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PN‑1007 (PPSGG) in the treatment of anti-MAG neuropathy, a disabling, chronic disorder of the peripheral nervous system. Orphan designation is granted to advance the development of… [read on]

  • April 27, 2020 General
    Polyneuron receives approval to begin clinical study with PN-1007 in anti-MAG neuropathy

    We are very proud to have received our first clinical trial application (CTA) approval in France, the Netherlands and the UK. We can now begin our planned phase I/IIa study of PN‑1007 for the treatment of anti-MAG neuropathy, a disabling, chronic disorder of… [read on]

  • April 7, 2020 General
    Polyneuron announces appointment of chief medical officer

    We are extremely pleased to welcome Dr Debra Barker to Polyneuron as our new chief medical officer. Dr Barker has a successful track record in drug development spanning over 25 years, involving many successful drug approvals. Press Release… [read on]

  • September 5, 2019 General
    Polyneuron annouces appointment of new Chairman

    Polyneuron announces the appointment of Ben Machielse as Chairman of the Board of Directors. Mr. Machielse supplements the strength of the Board following the appointments of David Mott of NEA and Graziano Seghezzi of Sofinnova Partners, who joined in March 2019 after the closing of… [read on]

  • March 28, 2019 Financing
    Polyneuron raises CHF 22.5 million in a major Series A financing

    Polyneuron raises CHF 22.5 million in an oversubscribed Series A financing to advance novel therapies for autoimmune diseases. Leading venture capital firm Sofinnova Partners led the Series A financing, together with New Enterprise Associates, which co-led the round  Press Release… [read on]


  • 1
  • 2
  • 3
  • 4
  • »
  • Last

Polyneuron |

Imprint | Privacy policy